In brief
In a major development for international health, members of the World Health Organization (WHO) have finalized a legally binding treaty designed to improve responses to future pandemics. This agreement comes as a response to the challenges faced during the Covid-19 outbreak, particularly concerning the disorganization and rivalry for resources. Central to the treaty is a commitment to the rapid sharing of data on emerging diseases, allowing researchers and pharmaceutical companies to expedite the development of vaccines and treatments.
WHO Director-General, Dr. Tedros Adhanom Ghebreyesus, hailed the agreement as a significant milestone in promoting a shared global commitment towards safety in health. He noted, “Member states have shown that multilateralism is still alive, indicating that nations can unite to address common threats." This treaty, reached after three years of discussions, marks only the second legally binding accord in the WHO's history, the first being a tobacco control agreement established in 2003. Although the pact remains subject to formal approval at next month’s World Health Assembly, its implications are already substantial. Notably, the United States, which announced its withdrawal from the WHO during President Trump's administration, will not be bound by the treaty’s terms post-2026.Under the terms of the agreement, nations will be responsible for ensuring that pandemic-related medicines are accessible globally during future outbreaks. Manufacturers will need to allocate at least 20% of their production of vaccines, therapeutics, and diagnostics to the WHO, with at least 10% offered as donations and the remainder available at affordable prices. Furthermore, the treaty includes provisions for the transfer of health technologies to lower-income countries, contingent on mutual agreements, which could enhance local production capabilities in times of health crises. However, this aspect of the agreement has sparked debate, especially given the frustrations expressed by developing nations over the vaccine distribution disparities witnessed during the COVID-19 pandemic. A core component of the treaty is the establishment of a Pathogen Access and Benefit-Sharing System (PABS), designed to streamline data sharing between pharmaceutical companies to facilitate rapid drug development in response to future health emergencies. As the world prepares for the potential threats that pandemics present, this new treaty symbolizes a hopeful step towards improved global health cooperation and preparedness.
